About Inflammasome Therapeutics
Inflammasome Therapeutics is a company based in Boston (United States) founded in 2009.. Inflammasome Therapeutics has raised $6.25 million across 5 funding rounds from investors including Gates Foundation. Inflammasome Therapeutics offers products and services including Inflammasome Therapies. Inflammasome Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Boston, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$6.25 M (USD)
in 5 rounds
-
Latest Funding Round
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Inflammasome Therapeutics
Inflammasome Therapeutics offers a comprehensive portfolio of products and services, including Inflammasome Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops treatments targeting Inflammasome for degenerative diseases
Unlock access to complete
Unlock access to complete
Funding Insights of Inflammasome Therapeutics
Inflammasome Therapeutics has successfully raised a total of $6.25M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Last Round
-
First Round
First Round
(16 Sep 2020)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2026 | Amount | Series B - Inflammasome Therapeutics | Valuation |
investors |
|
| Dec, 2024 | Amount | Series A - Inflammasome Therapeutics | Valuation |
investors |
|
| Aug, 2023 | Amount | Series A - Inflammasome Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Inflammasome Therapeutics
Inflammasome Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Gates Foundation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Charitable foundation investments on poverty reduction and healthcare
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Inflammasome Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Inflammasome Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Inflammasome Therapeutics Comparisons
Competitors of Inflammasome Therapeutics
Inflammasome Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Inflammasome Therapeutics
Frequently Asked Questions about Inflammasome Therapeutics
When was Inflammasome Therapeutics founded?
Inflammasome Therapeutics was founded in 2009 and raised its 1st funding round 11 years after it was founded.
Where is Inflammasome Therapeutics located?
Inflammasome Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Is Inflammasome Therapeutics a funded company?
Inflammasome Therapeutics is a funded company, having raised a total of $6.25M across 5 funding rounds to date. The company's 1st funding round was a Series A of $3.8M, raised on Sep 16, 2020.
What does Inflammasome Therapeutics do?
Inflammasome Therapeutics was founded in 2009 and is based in Boston, United States. Therapies targeting degenerative conditions such as Alzheimers disease, multiple sclerosis, macular degeneration, and type 2 diabetes are developed by the company. Focus is placed on eye diseases and neural disorders within the biotechnology sector. Operations involve research and development of treatments for these prevalent health issues.
Who are the top competitors of Inflammasome Therapeutics?
Inflammasome Therapeutics's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
What products or services does Inflammasome Therapeutics offer?
Inflammasome Therapeutics offers Inflammasome Therapies.
Who are Inflammasome Therapeutics's investors?
Inflammasome Therapeutics has 1 investor. Key investors include Gates Foundation.